A nano-luciferase expressing human coronavirus OC43 for countermeasure development.

"data availability data will be made available on request. acknowledgments this work was supported by an avidd u19ai171292 to r sb and t ps r01 ai132178"

"Declaration of Competing Interest T.P.S. has received funding from ViiV Healthcare and GlaxoSmithKline and has collaboratins with Ridgeback Biosciences and Gilead. R.S.B. is a member of the advisory board of VaxArt and Inviyd, and has collaborations with Takeda, Pfizer, Moderna, Ridgeback Biosciences, Gilead, and Eli Lily."

"This work was supported by an 10.13039/100000060NIAID AVIDD U19AI171292 to R.S.B and T.P.S, R01 AI132178 and R01 AI132178–04S1 to T.P.S. and R.S.B. D.R.M. is funded by a Hanna H. Gray Fellowship from the Howard Hughes Medical Institute. Meghan V. Diefenbacher: Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing. Thomas J. Baric: Investigation. David R. Martinez: Conceptualization. Ralph S. Baric: Conceptualization, Funding acquisition. Nicholas J. Catanzaro: Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing. Timothy P. Sheahan: Conceptualization, Data curation, Formal analysis, Funding acquisition, Writing – original draft, Writing – review & editing. T.P.S. has received funding from ViiV Healthcare and GlaxoSmithKline and has collaboratins with Ridgeback Biosciences and Gilead. R.S.B. is a member of the advisory board of VaxArt and Inviyd, and has collaborations with Takeda, Pfizer, Moderna, Ridgeback Biosciences, Gilead, and Eli Lily."